| Bioactivity | ABC1183 is an orally active selective dual GSK3 and CDK9 inhibitor. ABC1183 inhibits GSK3β, GSK3α and CDK9/cyclin T1 with the IC50 values of 657 nM, 327 nM and 321 nM, respectively. ABC1183 has anti-inflammatory and anti-tumor activities[1]. | ||||||||||||
| Invitro | ABC1183 (3 μM, 24 h) can block cell cycle progression and thus affect cell proliferation[1]. Cell Cycle Analysis[1] Cell Line: | ||||||||||||
| In Vivo | ABC1183 (oral gavage, 5 or 50 mg/kg) inhibits tumor proliferation through negative regulation of cell growth and pro-inflammatory signalling in male C57BL/6 mice[1]. Animal Model: | ||||||||||||
| Name | ABC1183 | ||||||||||||
| CAS | 1042735-18-1 | ||||||||||||
| Formula | C18H14N4OS | ||||||||||||
| Molar Mass | 334.39 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Randy S Schrecengost，et al. In Vitro and In Vivo Antitumor and Anti-Inflammatory Capabilities of the Novel GSK3 and CDK9 Inhibitor ABC1183. J Pharmacol Exp Ther. 2018 Apr;365(1):107-116. |